ABSTRACT

Background: We conducted a comparative assessment of the productivity loss associated with the two different treatment options for Dupuytren’s disease: collagenase and fasciectomy.

Methods: The retrospective claims analysis was performed using the data from IBM MarketScan® Commercial (CD) and Health and Productivity Management (HPM) Databases over five years (2012–2016). We identified two cohorts of patients who underwent either collagenase or fasciectomy in the CD. Propensity-score matched patients were linked to their productivity loss claims in the HPM database. Productivity loss measures were assessed over a 12-month follow-up period.

Results: Out of 702 collagenase and 999 fasciectomy propensity score-matched patients in the CD, there were 147 collagenase and 273 fasciectomy patients in the HPM database. Over the follow-up period, collagenase-treated patients were significantly less likely to use short-term disability (STD) leave (9.7% vs. 20.2%; P = 0.009), reflecting in the lower average number of absent STD days (mean, 2.8 vs. 8.1; P = 0.002) in comparison to fasciectomy-treated. The mean indirect STD cost was considerably lower in the collagenase vs. fasciectomy group ($375 vs. $1,108; P = 0.002).

Conclusion: This study indicates that collagenase vs. fasciectomy treatment may be related to a lower rate of workplace absence and lower indirect cost in a year following the treatment.

摘要

背景：我们对与Dupuytren病的两种不同治疗方案相关的生产力损失进行了比较评估：胶原酶和筋膜切除术。

方法：回顾性索赔分析是使用IBMMarketScan®商业（CD）和健康与生产力管理（HPM）数据库五年（2012-2016年）中的数据进行的。我们确定了CD中接受过胶原酶或筋膜切除术的两组患者。倾向得分匹配的患者与他们在HPM数据库中的生产力损失索赔相关联。在12个月的随访期内评估了生产力下降的措施。

结果：CD中有702个胶原酶和999个筋膜切除术倾向评分匹配的患者中，HPM数据库中有147个胶原酶和273个筋膜切除术患者。在随访期内，接受胶原酶治疗的患者使用短期残疾（STD）假的可能性显着降低（9.7％vs. 20.2％; P = 0.009），这反映出平均无病性病天数减少（平均与筋膜切除术治疗组相比，分别为2.8对8.1；P = 0.002）。与筋膜切除术组相比，胶原酶的平均间接STD费用要低得多（$ 375 vs. $ 1,108；P = 0.002）。

结论：这项研究表明，胶原酶与筋膜切除术的治疗可能与治疗后一年内工作场所缺勤率降低和间接成本降低有关。